Dr Kathryn Schmitz
@fitaftercancer
Leading #ExerciseOncology researcher Interim Director @UPMCHillmanCC. Past Prez @ ACSM. Mom. Former Martha Graham Dancer. Confirmed Goofball. Views=mine.
So proud of this remarkable work from the Meisel lab @UPMCHillmanCC Exercise-induced microbiota metabolite enhances CD8 T cell antitumor i... sciencedirect.com/science/articl…
🗓️Join us Monday, August 4, 2025, for the Survivorship After Cancer of the Head and Neck: A Multidisciplinary Symposium — hosted at The Assembly, Thomas E. Richards Auditorium in Pittsburgh, PA, with both in-person and virtual options available. @OtoPitt @UPMCHillmanCC
It's easy to recommend exercise for better overall health but I had a truly remarkable day in clinic empowering patients with colon cancer to follow an evidence-based, post-op fitness program that offers a survival benefit on par with some chemo drugs Bodies in motion, indeed!
📰 New @scisignal article from @PittVMI and @UPMCHillmanCC researchers suggests STIM2 loss may be a biomarker of more aggressive colorectal cancer. Read more👇
New work shows how loss of the calcium-sensing protein STIM2 can worsen outcomes in colorectal cancer and support tumor #metastasis and hint that the protein could be used as a potential prognostic marker. @TrebakM @Trayambak_P @PittDeptofMed scim.ag/44v3O3E
Incredible milestone for MSS CRC! 🙌 Congratulations to @AnwaarSaeed3, Dr. Hecht, and the entire STELLAR-303 team on this historic achievement. A huge leap forward for IO in GI oncology. Truly inspiring work! 👏🎯 #CRC #Immunotherapy #STELLAR303 #OncologyInnovation
🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis for the trust & Dr. Hecht for leading this global win with me! 🎉 @UPMCHillmanCC ir.exelixis.com/news-releases/…
A $1.5M gift from grateful patient, Jacqueline "Jackie" Shoener, will advance sarcoma research at UPMC Hillman Cancer Center through the establishment of the Dr. John A. Shoener Family Endowed Research Fund for Sarcoma. Read what inspired Jackie's gift: hillmanpowerofhope.org/stories-of-hop…
.@UPMCHillmanCC, University of Pittsburgh melanoma researcher receives endowed immunotherapy award cancerletter.com/in-brief/20250…
My book, Moving Through Cancer, has been translated into Chinese!
So honored! See you at @ACRMtweets
Congratulations to the Distinguished Lecturer in #Cancer #Rehabilitation & #Survivorship Care, Kathryn H. Schmitz, PhD, MPH, FACSM, FTOS, FSBM, FNAK, FSEM She is an author of the book Moving through Cancer @fitaftercancer Register for #ACRM2025 conference.acrm.org
Thank you @fitaftercancer for posting. We created a video companion for the CHALLENGE Trial results here: x.com/oncologytube/s…
🚨 CHALLENGE Trial video at ASCO 2025!🚨 🚶♀️ 3-yr exercise: 28% less recurrence (HR 0.72, p=0.02). 📊 8-yr OS: 90.3% (exercise) vs 83.2% (control), HR 0.63. 📈 Liver recurrence: 3.6% vs 6.5%; new cancers: 5.2% vs 9.7%. 📰ARTICLE: oncologytube.com/challenge-tria… 📺YOUTUBE:…
Interested in new therapies for melanoma? Dr. Jason Luke @jasonlukemd presents at an Ed Session this afternoon @ASCO. @UPMCnews @UPMCPhysicianEd
My chat with @Breastcancerorg at ASCO breastcancer.org/podcast/making…
Exercise is medicine. #ASCO25
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…
What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72…
#ASCO25 #OncTwitter #crcsm NEW: Randomized trial of exercise vs health ed in people w/ colon cancer post adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆 #OncoAlert
A standing ovation for #CHALLENGE trial at #ASCO25 - first in world to definitively show exercise reduces recurrence and improves survival: “For every 16 people, exercise prevents 1 person from recurrent/new cancer” “For every 14 people, exercise prevents 1 person from dying”
#ASCO25 #plenary If the graph on the left is practice changing, the graph on the right is urgently practice changing. Cost to health systems-$15K to $18K a month vs $100-$150 a month. ATOMIC trial vs CHALLENGE trial.
Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25
Kudos to @NEJM for publishing a non-drug intervention. Exercise improves both disease free & overall survival for patients with colon cancer who finished surgery & chemotherapy.
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…